| Preface to the First Edition |
|
ix | |
| Preface to the Sixth Edition |
|
xi | |
|
|
|
xiii | |
| Dedication |
|
xxvii | |
|
PART I Principles of Immune Response |
|
|
|
1 The Human Immune Response |
|
|
2 | (15) |
|
|
|
|
|
2 Organization of the Immune System |
|
|
17 | (22) |
|
|
|
|
|
|
|
|
|
39 | (16) |
|
|
|
|
|
4 Antigen Receptor Genes, Gene Products, and Co-Receptors |
|
|
55 | (23) |
|
|
|
|
|
|
|
5 The Major Histocompatibility Complex |
|
|
78 | (15) |
|
|
|
|
|
6 Antigens and Antigen Presentation |
|
|
93 | (14) |
|
|
|
|
|
7 B-Cell Development and Differentiation |
|
|
107 | (13) |
|
|
|
|
|
|
|
8 Immunoglobulin Function |
|
|
120 | (10) |
|
|
|
|
|
130 | (7) |
|
|
|
|
|
10 T-Cell Activation and Tolerance |
|
|
137 | (14) |
|
|
|
11 Helper T-Cell Subsets and Control of the Inflammatory Response |
|
|
151 | (11) |
|
|
|
|
|
12 Cytotoxic T Lymphocytes and Natural Killer Cells |
|
|
162 | (13) |
|
|
|
|
|
13 Regulatory Immune Cells |
|
|
175 | (11) |
|
|
|
|
|
14 Cytokines and Cytokine Receptors |
|
|
186 | (29) |
|
|
|
|
|
|
|
|
|
15 Chemokines and Chemokine Receptors |
|
|
215 | (13) |
|
|
|
16 Lymphocyte Adhesion and Trafficking |
|
|
228 | (11) |
|
|
|
|
|
17 Death Pathways and Immunogenicity |
|
|
239 | (10) |
|
|
|
|
|
|
|
PART II Fundamentals of Host-Environmental Interactions |
|
|
|
18 Human Genomics in Immunology |
|
|
249 | (9) |
|
|
|
|
|
19 Regulatory RNA in Immunologic Diseases |
|
|
258 | (7) |
|
|
|
|
|
265 | (7) |
|
|
|
|
|
|
|
21 Immune Deficiencies at the Extremes of Age |
|
|
272 | (9) |
|
|
|
|
|
|
|
22 The Microbiota in Immunity and Inflammation |
|
|
281 | (14) |
|
|
|
PART III Host Defenses to Infectious Agents |
|
|
|
23 Immunology of the Skin |
|
|
295 | (11) |
|
|
|
|
|
|
|
24 Immunology of Mucosal Surfaces |
|
|
306 | (14) |
|
|
|
|
|
25 Host Defenses to Viruses |
|
|
320 | (11) |
|
|
|
|
|
26 Host Defenses to Intracellular Bacteria |
|
|
331 | (16) |
|
|
|
|
|
27 Host Defenses to Extracellular Bacteria, Including Spirochetes |
|
|
347 | (14) |
|
|
|
|
|
|
|
|
|
28 Host Defenses to Fungi |
|
|
361 | (14) |
|
|
|
|
|
|
|
29 Host Defenses to Protozoa |
|
|
375 | (11) |
|
|
|
|
|
|
|
30 Host Defenses to Helminth Infection |
|
|
386 | (13) |
|
|
|
|
|
31 Emerging Pandemic Infectious Disease Threats |
|
|
399 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART IV Immune Deficiency and Immune Regulatory Disorders |
|
|
|
32 Approach to the Evaluation of the Patient With Suspected Immunodeficiency |
|
|
413 | (7) |
|
|
|
|
|
33 Primary Antibody Deficiencies |
|
|
420 | (18) |
|
|
|
|
|
34 Primary T-Cell Immunodeficiencies |
|
|
438 | (19) |
|
|
|
35 Genetic Disorders of Interferons-, Interleukin-17, Interleukin-18, and Nuclear Factor-kB-Mediated Immunity |
|
|
457 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36 Hemophagocytic Lymphohistiocytosis |
|
|
469 | (5) |
|
|
|
|
|
37 Autoinflammatory Syndromes |
|
|
474 | (10) |
|
Catharina M. Mulders-Manders |
|
|
Jeroen C. H. van der Hilst |
|
|
|
|
|
|
38 Immune Regulatory Disorders |
|
|
484 | (7) |
|
|
|
|
|
39 Neutrophils and Neutrophil Disorders |
|
|
491 | (15) |
|
|
|
|
|
40 Complement and Complement Disorders |
|
|
506 | (19) |
|
|
|
|
|
|
|
|
|
41 Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome |
|
|
525 | (17) |
|
|
|
|
|
|
|
42 Autoantibody-Mediated Phenocopies of Primary Immunodeficiency Diseases |
|
|
542 | (9) |
|
|
|
|
|
|
|
|
|
|
43 Allergic Airway Diseases |
|
|
551 | (10) |
|
|
|
|
|
|
|
44 Mast Cells and Mast Cell Disorders |
|
|
561 | (12) |
|
|
|
|
|
|
|
45 Eosinophils and Eosinophilic Disorders |
|
|
573 | (13) |
|
|
|
|
|
46 Urticaria, Angioedema, and Anaphylaxis |
|
|
586 | (15) |
|
|
|
|
|
47 Allergic Reactions to Stinging and Biting Insects |
|
|
601 | (8) |
|
|
|
|
|
48 Atopic and Contact Dermatitis |
|
|
609 | (14) |
|
|
|
|
|
|
|
|
|
623 | (7) |
|
|
|
|
|
|
|
630 | (19) |
|
|
|
|
|
|
|
PART VI Systemic Immune Diseases |
|
|
|
51 Mechanisms of Autoimmunity |
|
|
649 | (8) |
|
|
|
|
|
|
|
52 Systemic Lupus Erythematosus |
|
|
657 | (21) |
|
|
|
|
|
|
|
|
|
678 | (15) |
|
|
|
54 Juvenile Idiopathic Arthritis |
|
|
693 | (11) |
|
|
|
|
|
|
|
|
|
704 | (8) |
|
|
|
|
|
|
|
56 Scleroderma-Systemic Sclerosis |
|
|
712 | (11) |
|
|
|
|
|
57 Inflammatory Muscle Diseases |
|
|
723 | (11) |
|
|
|
|
|
|
|
734 | (20) |
|
|
|
|
|
59 Small- and Medium-Vessel Primary Vasculitis |
|
|
754 | (19) |
|
|
|
|
|
|
|
|
|
60 Large Vessel Vasculitides |
|
|
773 | (15) |
|
|
|
61 Antiphospholipid Syndrome |
|
|
788 | (8) |
|
Molly M. Daughety Doruk Erkan |
|
|
|
|
|
|
PART VII Organ-Specific Inflammatory Disease |
|
|
|
62 Immunohematologic Disorders |
|
|
796 | (10) |
|
|
|
|
|
63 Bullous Diseases of the Skin and Mucous Membranes |
|
|
806 | (18) |
|
|
|
|
|
64 Immunology of Psoriasis |
|
|
824 | (8) |
|
|
|
|
|
832 | (11) |
|
|
|
|
|
|
|
|
|
843 | (11) |
|
|
|
|
|
67 Autoimmune Peripheral Neuropathies |
|
|
854 | (12) |
|
|
|
68 Immunologic Renal Diseases |
|
|
866 | (17) |
|
|
|
|
|
|
|
69 Immunologic Mechanisms of Atherosclerosis and Myocarditis |
|
|
883 | (15) |
|
|
|
|
|
70 Autoimmune Thyroid Diseases |
|
|
898 | (11) |
|
|
|
|
|
|
|
|
|
909 | (10) |
|
|
|
72 Immunologic Lung Diseases |
|
|
919 | (17) |
|
|
|
|
|
|
|
73 Chronic Obstructive Pulmonary Disease and Emphysema |
|
|
936 | (7) |
|
|
|
|
|
|
|
74 Immunologic Ocular Disease |
|
|
943 | (16) |
|
|
|
|
|
75 Immunologic Diseases of the Gastrointestinal Tract |
|
|
959 | (13) |
|
|
|
76 Inflammatory Hepatobiliary Diseases |
|
|
972 | (12) |
|
Benedetta Terziroli Beretta-Piccoli |
|
|
|
|
|
|
|
|
PART VIII Immunology and Immunotherapy of Neoplasia |
|
|
|
|
|
984 | (16) |
|
|
|
|
|
|
|
|
|
|
|
1000 | (14) |
|
|
|
|
|
|
|
|
|
79 Monoclonal Gammopathies |
|
|
1014 | (14) |
|
|
|
80 Immune Responses to Solid Tumors and Immune Checkpoint Therapy |
|
|
1028 | (14) |
|
|
|
|
|
|
|
|
|
1042 | (9) |
|
|
|
PART IX Medical Management of Immunological Diseases |
|
|
|
82 Immunoglobulin Therapy: Replacement and Immunomodulation |
|
|
1051 | (10) |
|
|
|
|
|
1061 | (11) |
|
|
|
|
|
84 Immunomodulating Drugs |
|
|
1072 | (8) |
|
|
|
|
|
85 Protein Kinase Antagonists |
|
|
1080 | (9) |
|
|
|
|
|
|
|
|
|
86 Biologic Response Modifiers |
|
|
1089 | (13) |
|
|
|
|
|
|
|
1102 | (15) |
|
|
|
|
|
|
|
|
|
88 Allergen Immunotherapy for Allergic Diseases |
|
|
1117 | (11) |
|
|
|
|
|
|
|
|
89 Solid Organ Transplantation: Rejection, Immunosuppression, and Tolerance |
|
|
1128 | (18) |
|
|
|
|
|
|
|
90 Allogeneic Transplantation for Immunodeficiency |
|
|
1146 | (15) |
|
|
|
91 Gene Therapy for Primary Immune Deficiency Diseases |
|
|
1161 | (11) |
|
|
|
|
|
92 Hematopoietic Stem Cell Transplantation for Malignant Diseases |
|
|
1172 | (13) |
|
|
|
|
|
|
|
PART XI Diagnostic Immunology |
|
|
|
|
|
1185 | (13) |
|
Cristiane J. Nunes-Santos |
|
|
|
|
|
|
94 Assessment of Functional Immune Responses in Lymphocytes |
|
|
1198 | (16) |
|
|
|
95 Assessment of Neutrophil Function |
|
|
1214 | (11) |
|
|
|
|
|
96 Assessment of Human Allergic Diseases |
|
|
1225 | (10) |
|
|
| Appendix 1 Selected CD Molecules and Their Characteristics |
|
1235 | (6) |
|
|
| Appendix 2 Laboratory Reference Values |
|
1241 | (2) |
|
|
| Index |
|
1243 | |
